Nonclinical Aspects of Dermal Safety Testing

Barbara Hill, Ph.D.
Supervisory Pharmacologist/Toxicologist
Division of Dermatology and Dental Products
September 10, 2018
Disclaimer

This presentation reflects the views of the author and should not be construed to represent FDA’s views or policies.

Presenter has no conflicts to disclose.
Nonclinical Studies for Assessing Dermal Safety of Topical Drug Products

- Dermal irritation studies
- Dermal sensitization studies
- Ocular irritation studies
- Dermal photosafety studies
Dermal Irritation

• Stand-alone dermal irritation studies are no longer recommended because such information can be obtained from other studies; This also supports implementation of the 3Rs (replacement, reduction and refinement of animal use)

• Recommend evaluation of dermal irritation be incorporated into repeat-dose dermal toxicology studies (typically minipigs)

• In vitro assays used as screen for in vivo
Dermal Sensitization

- A dermal sensitization study in guinea pigs, using clinical formulation
- The murine Local Lymph Node Assay (LLNA) is no longer recommended due to limitations of the assay (high false positive rate)
  - We will review a submitted LLNA for a topical drug product and accept the outcome particularly if the result is negative
- In vitro assays used as screen for in vivo
  - A battery of tests with different endpoints
Ocular Irritation

• The in vivo rabbit ocular irritation test is no longer recommended
• The ocular irritation potential should be tested using appropriate ex vivo or in vitro methods
• The bovine corneal opacity and permeability (BCOP) assay is currently recommended
  – The evaluation should consider the active ingredient and the finished formulation
• Dermal irritant is assumed to be ocular irritant
  – No test needed
Photosafety Introduction

• ICH S10 guidance (January 2015)
  – *Photosafety Evaluation of Pharmaceuticals*

• Effects related to Photosafety
  – Phototoxicity (photoirritation): An acute light-induced tissue response to a photoreactive chemical
  – Photoallergy: An immunologically mediated reaction to a chemical, initiated by the formation of photoproducts (e.g., protein adducts) following a photochemical reaction
Nonclinical Photosafety Assessment

- Focus on nonclinical photosafety assessment for topical drug products applied to sun exposed skin
- In vitro nonclinical phototoxicity assessment
- In vivo nonclinical phototoxicity assessment
- A photoallergy study in animals is not recommended
  - Not predictive of clinical effects
- Photogenotoxicity and photocarcinogenicity testing is not recommended
  - Not predictive of clinical effects
Photochemical Properties

• Absorption of photons at any wavelength between 290 and 700 nm
• Has a molar extinction coefficient (MEC) greater than 1000 mol\(^{-1}\) cm\(^{-1}\) at any wavelength between 290 and 700 nm
• If either condition is not met, then not considered to be sufficiently photoreactive to result in direct phototoxicity
• No further nonclinical or clinical testing required
Photochemical Reactivity

• Excitation by light can lead to generation of reactive oxygen species (ROS)
  – Superoxide anion and singlet oxygen

• ROS generation following irradiation with UV-visible light (i.e., wavelength between 290 and 700 nm) can be an indicator of phototoxicity potential
Nonclinical Phototoxicity Studies
In Vitro

• 3T3 Neutral Red uptake assay (cytotoxicity assay)
  – For soluble compounds, most widely used
  – High false positive rate
  – If negative, then no concern; If positive, then follow-up

• ROS assay (chemical assay)
  – ROS assay is qualified for certain contexts of use
  – Limitations must be taken into consideration
  – High false positive rate

• Other in vitro models (e.g., human skin models)
  – Not many submitted
Decision Tree for in Vitro Nonclinical Phototoxicity Studies

• Absorption at any wavelength between 290 and 700 nm with a MEC greater than 1000 mol\(^{-1}\) cm\(^{-1}\)
• Conduct 3T3 Neutral Red uptake assay
• Negative – No further nonclinical testing, inform clinical review team
• Positive – Follow up in vivo nonclinical testing
Nonclinical Phototoxicity Studies In Vivo

- Acceptable animal species: mouse, rat, guinea pig
- Apply clinical formulation to the skin followed by simulated solar light exposure
- Signs of phototoxicity should be evaluated based on relevant endpoints at appropriate timepoints
  - Erythema, edema, eschar at the treatment site
  - Evaluated over hours to days
Decision Tree for in Vivo Nonclinical Phototoxicity Studies

- Absorption at any wavelength between 290 and 700 nm with a MEC greater than 1000 mol\(^{-1}\) cm\(^{-1}\)
- Conduct in vivo animal phototoxicity study
- Negative or Positive – No further nonclinical testing, inform clinical review team
Positive Nonclinical Phototoxicity Reactions

- Inform subjects in Investigator’s Brochure/Informed Consent
- Photosafety testing in human clinical studies with the to-be-marketed formulation
- Labeling should include a precaution to avoid sun exposure
Negative Nonclinical Phototoxicity Reactions

- No information for subjects in Investigator’s Brochure/Informed Consent
- In US, photosafety testing in human clinical studies with the to-be-marketed formulation
- Information in labeling depends on results of clinical photosafety studies
Questions?